Carbetocin Injection 100mcg/ml
Cinomac Injection
Cinomac Injection is a prescribed for the prevention of postpartum haemorrhage because of the uterine atony.Cinomac Injection Composition :-
Cinomac Injection combination :Carbetocin ........................................... 100mcg/ml
Carbetocin is a long acting oxytocin agonist.
Some common side effects like -
• Nausea,
Carbetocin is a long acting oxytocin agonist.
Cinomac Injection Dosage forms & Strength :-
Cinomac Injection 1ml of consisting 100 micrograms carbetocin for intravenous or intramuscular administration.
Cinomac Injection Uses :-
Cinomac Injection i used to prevention of postpartum haemorrhage because of the uterine atony.How to Use Cinomac Injection :-
• Cinomac Injection 1ml is to be given by intravenous injection only under adequate medical supervision.
Vaginal delivery :
• Cinomac Injection 1ml is to be given by intravenous injection or intramuscular injection, under adequate medical supervision.
• Cinomac Injection should only be only be administered after delivery of the new born baby, and as soon as possible after delivery, ideally before the delivery of the placenta.
• For intravenous administration Cinomac Injection should be administered slowly, over 1 minute.
• Cinomac Injection is intentional or single use only. No further doses of Cinomac Injection must be administered.
How Dose Cinomac Injection Work :-
Cinomac Injection is a combination of : carbetocin.Carbetocin are those of a long acting oxytocin agonist.
Carbetocin selectively binds to oxytocin receptors in the smooth muscle of the uterus, stimulates rhythmic contractions of the uterus, grow the frequency of existing contractions, and increase the tone of the uterus musculature.
On the postpartum uterus, carbetocin is capable of raising the rate and force of spontaneous uterine contractions. The start of uterine contraction following carbetocin is fast after intravenous or intramuscular administration, with a firm contraction being obtained within 2 minutes.
A single 100 micrograms intravenous or intramuscular dose of carbetocin administered after the delivery of the infant is sufficient to control adequate uterine contraction that cure uterine atony and more bleeding comparable with an oxytocin infusion stay for several hours.
Cinomac Injection Sideeffects :-
Like all medicines, Cinomac Injection can cause side effects, however not everyone may experience these side effects.Some common side effects like -
• Nausea,
• Abdominal pain,
• Pruritus,
• Flushing,
• Vomiting,
• Geeling of warmth,
• Hypotension,
• Headache,
• Tremor and there can be many other side effects as well as some side effects. Those that have not been mentioned. However, if you have any experience of any sideeffets and if they do not reduce then consult your doctor.
Precautions :-
• There is no suitable use of Cinomac Injection in children below 12 years of age.The safety and success of Cinomac Injection in adolescents has not yet been established.
Contraindications :
• During pregnancy and labour before delivery of the new born baby.
• Cinomac Injection should not be used for the induction of labour.
• Hypersensitivity to carbetocin or to any of the excipients listed in section.
Hepatic or renal disease,
Critical cardiovascular disorders,
Epilepsy.
• The use of Cinomac Injection at any condition before delivery of the new born is not appropriate because its uterotonic activity continue for several hours. This is in marked contrast to the fast reduction of effect observed after discontinuation of an oxytocin infusion.
• In case of continuous vaginal or uterine bleeding after administration of Cinomac Injection the cause must be determined. Consideration should be given to causes like retained placental fragments, perineal, vaginal and cervix lacerations, inadequate repair of the uterus, or disorders of blood coagulation.
• Cinomac Injection is a single administration only, intramuscular or intravenous. In case of intravenous administration, it must be administered slowly over 1 minute. In case of persisting uterine hypotonia or atonia and the consequent excessive bleeding, additional therapy with another uterotonic must be considered. There are no data on additional doses of carbetocin or on the use of carbetocin following continue uterine atony after oxytocin.
• Cinomac Injection to possess some antidiuretic activity and therefore the possibility of hyponatraemia are not excluded, specialy in patients also receiving large volumes of intravenous fluids. The early signs of drowsiness, listlessness and headache should be recognised to cure convulsions and coma.
• In general, Cinomac Injection should be used carefully in the presence of migraine, asthma and cardiovascular disease or any condition in which a quick addition to extracellular water can generate hazard for an already overburdened system. The decision of administering carbetocin can be made by the physician after carefully weighing the potential benefit carbetocin can provide in these specific cases.
• There is no data available on the use of Cinomac Injection in patients with eclampsia. Patients with eclampsia and pre-eclampsia must be carefully monitored.
• Particular studies have not been undertaken in gestational diabetes mellitus.
• Cinomac Injection has been administered in connection with a number of analgesics, spasmolytics and agents used for epidural or spinal anaesthesia, and no drug interactions have been specify.
• Critical hypertension has been reported when oxytocin was given 3 to 4 hours following prophylactic administration of a vasoconstrictor in conjunction with caudal-block anaesthesia.
• During mixture with ergot-alkaloids, like methylergometrine, oxytocin and carbetocin can enhance the blood pressure enhancing effect of these agents. If oxytocin or methylergometrine are administered after carbetocin there can be a risk of cumulative exposure.
• Since it has been found that prostaglandins potentiate the effect of oxytocin, it is expected that this can also take place with Cinomac Injection. Therefore, it is not suggested that prostaglandins and carbetocin be used together. If they are concomitantly administered, the patient should be carefully monitored.
• Some inhalation-anesthetics, like halothane and cyclopropane can enhance the hypotensive effect and weaken the effect of carbetocin on the uterus. Arrhythmias have been reported for oxytocin during concomitant use.
• Pregnancy
Cinomac Injection is contraindicated during pregnancy and must not be used for the induction of labour.
• Breastfeeding
No important effects on milk let-down have been reported during clinical trials. Small amounts of Cinomac Injection have been shown to pass from plasma into breast milk of nursing women. The small amounts transferred into colostrum or breast milk after a single injection of Cinomac Injection, and subsequently ingested by the newborn are assumed to be degraded by enzymes in the gut.
Breast-feeding does not need to be limited after the use of carbetocin.
Cinomac Injection Price :-
MRP ₹ : = 375.00 ( 1ml )Cinomac Injection Marketed By :-
Macleods Pharmaceuticals Pvt LtdCinomac Injection Self-life :-
Please see the expiry date/manufacture date printed on Cinomac Injection pack.Cinomac Injection Storage :-
Room temperature stable up to 30° C.
Classification :-
Drug Name : Carbetocin,
Therapeutic Indication : Prevention of Postpartum Bleeding,
Therapeutic Class : Long acting oxytocin agonist,